| Bioactivity | FZ-AD005 is a DLL3 target ADC compound containing a novel anti-DLL3 antibody, FZ-A038, and a valine–alanine (Val–Ala) dipeptide linker. FZ-AD005 can used in the research of small cell lung cancer[1]. |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Qingsong Guo, et al. FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28;23(10):1367–1377. |